Liu Hui

Director/Board Member at RALLYBIO CORPORATION

Net worth: 207 157 $ as of 2026-09-29

53 year

Health Technology

Consumer Services

Profile

Dr. Liu Hui is an Independent Director at Rallybio Corp.
He is on the Board of Directors at Rallybio Corp.
Dr. Hui was previously employed as a Chief Business Officer & Executive Vice President by Merus NV and a VP & Head-Business Development & Licensing by Novartis AG.
He received his undergraduate degree from Peking University, an MBA from the University of Michigan and a doctorate degree from the University of Michigan.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
RALLYBIO CORPORATION 0.23%	2026-09-23	12,044 ( 0.23% )	207 157 $	2026-09-29

Liu Hui active positions

Companies	Position	Start
RALLYBIO CORPORATION	Director/Board Member	2022-04-03

All active positions of Liu Hui

Former positions of Liu Hui

Companies	Position	End
MERUS N.V.	Corporate Officer/Principal	2024-06-30
NOVARTIS AG	Corporate Officer/Principal	2014-12-31

See the detail of Liu Hui's experience

Education of Liu Hui

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Liu Hui's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Novartis AG Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products	Health Technology
Peking University Peking University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Michigan University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Merus NV Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment	Health Technology
Rallybio Corp. Rallybio Corp. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that engages in research, development and commercialization of therapies for patients with severe & rare diseases	Health Technology